Literature DB >> 12858438

Increased risk of tuberculosis in patients with rheumatoid arthritis.

Loreto Carmona1, César Hernández-García, Cristina Vadillo, Esperanza Pato, Alejandro Balsa, Isidoro González-Alvaro, Miguel Angel Belmonte, Xavier Tena, Raimon Sanmartí.   

Abstract

OBJECTIVE: To quantify the risk of tuberculosis (TB) in an unselected sample of patients with rheumatoid arthritis (RA) compared to the risk in the general population.
METHODS: The incidence of TB in the general population of Spain was obtained from the National Network of Epidemiological Surveillance reports. The incidence of TB was ascertained from a cohort of 788 patients with RA selected randomly from the registries of 34 participating centers throughout Spain. A patient was considered a TB case only if information about disease symptoms, microorganism identification, and TB treatment were confirmed in the clinical records. The relative risk of TB in RA was calculated by dividing the standardized mean incidence of TB from 1990 to 2000 in the RA cohort by the mean incidence of TB in Spain during the same years.
RESULTS: The mean incidence of TB in the general population of Spain from 1990 to 2000 was 23 cases per 100,000. Seven cases of TB were identified in the RA cohort, yielding a mean annual incidence (1990-2000) of 134/100,000 patients. The incidence risk ratio of pulmonary TB in patients with RA compared to the general population is 3.68 (95% CI 2.36-5.92).
CONCLUSION: We found a 4-fold increased risk of TB infection in patients diagnosed with RA. These results might help to interpret the magnitude of the problem attributable to the introduction of new therapies in RA.

Entities:  

Mesh:

Year:  2003        PMID: 12858438

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  44 in total

Review 1.  Anti-tumour necrosis factor alpha therapy in rheumatoid arthritis: an update on safety.

Authors:  K L Hyrich; A J Silman; K D Watson; D P M Symmons
Journal:  Ann Rheum Dis       Date:  2004-07-08       Impact factor: 19.103

2.  Prevalence and clinical characteristics of tuberculosis in rheumatoid arthritis patients.

Authors:  Fadoua Allali; Hanane Rkain; Afaf Faik; Selma El Hassani; Najia Hajjaj-Hassouni
Journal:  Clin Rheumatol       Date:  2004-12-03       Impact factor: 2.980

3.  Dual mycobacterial infection in the setting of leflunomide treatment for rheumatoid arthritis.

Authors:  S Agrawal; A Sharma
Journal:  Ann Rheum Dis       Date:  2007-02       Impact factor: 19.103

4.  Increased risk of tuberculosis in patients with rheumatoid arthritis in Japan.

Authors:  T Yamada; A Nakajima; E Inoue; E Tanaka; M Hara; T Tomatsu; N Kamatani; H Yamanaka
Journal:  Ann Rheum Dis       Date:  2006-07-12       Impact factor: 19.103

5.  IGRA testing in patients with immune-mediated inflammatory diseases: which factors influence the results?

Authors:  Juan González-Moreno; Mercedes García-Gasalla; Inés Losada-López; Carmen Cifuentes Luna; Isabel Mir Viladrich; Victoria Fernández-Baca; Araceli Serrano; Antonio Juan Mas; Joan Riera-Oliver; Antoni Payeras Cifre
Journal:  Rheumatol Int       Date:  2017-10-19       Impact factor: 2.631

6.  Methotrexate treatment in rheumatoid arthritis: management in clinical remission, common infection and tuberculosis. Results from a systematic literature review.

Authors:  Mónica Bogas; Pedro Machado; Ana Filipa Mourão; Lúcia Costa; Maria José Santos; João Eurico Fonseca; José António P Silva; Helena Canhão
Journal:  Clin Rheumatol       Date:  2010-02-08       Impact factor: 2.980

7.  Biologic therapy for inflammatory arthritis and latent tuberculosis: real world experience from a high prevalence area in the United Kingdom.

Authors:  Muhammad K Nisar; Aneesa Rafiq; Andrew J K Östör
Journal:  Clin Rheumatol       Date:  2015-10-24       Impact factor: 2.980

Review 8.  Leveraging the electronic health record to improve quality and safety in rheumatology.

Authors:  Gabriela Schmajuk; Jinoos Yazdany
Journal:  Rheumatol Int       Date:  2017-08-29       Impact factor: 2.631

9.  Positiveness of purified protein derivatives in rheumatoid arthritis patients who are not receiving immunosuppressive therapy.

Authors:  Ilhan Sezer; Hilal Kocabas; Meltem Alkan Melikoglu; Mehmet Arman
Journal:  Clin Rheumatol       Date:  2008-08-08       Impact factor: 2.980

Review 10.  Epidemiological studies in incidence, prevalence, mortality, and comorbidity of the rheumatic diseases.

Authors:  Sherine E Gabriel; Kaleb Michaud
Journal:  Arthritis Res Ther       Date:  2009-05-19       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.